Timir Datta-Chaudhuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Timir Datta-Chaudhuri has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Stavros Zanos
Northwell Health, New Hyde Park, USA
14 shared publications Pamela Abshire
Department of Electrical and Computer Engineering, University of Maryland, College Park
12 shared publicationsJason Wong
Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research and Northwell Health, Manhasset, NY, USA
11 shared publications- Yao-Chuan Chang
Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, 11030, USA
6 shared publications - Ibrahim T. Mughrabi
Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Northwell Health, 350 Community Drive, Manhasset, NY 11030, USA
5 shared publications Kevin J. Tracey
Feinstein Institutes for Medical Research, Northwell Health Manhasset NY
5 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Author Correction: Control of spatiotemporal activation of organ-specific fibers in the swine vagus nerve by intermittent interferential current stimulation
- 13 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAuthor Correction: Control of spatiotemporal activation of organ-specific fibers in the swine vagus nerve by intermittent interferential current stimulation
- Open Access
- 7 March 2026
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 12 (1) , 8
A robust, real‑time telemetry protocol for miniaturized neural implants using off‑the‑shelf hardware
Wireless telemetry from fully implanted, millimeter-scale neuromodulation devices is constrained by tight power budgets, inefficient antennas, and in-body
- 7 March 2026
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 12 (1) , 8
Open AccessA robust, real‑time telemetry protocol for miniaturized neural implants using off‑the‑shelf hardware
Wireless telemetry from fully implanted, millimeter-scale neuromodulation devices is constrained by tight power budgets, inefficient antennas, and in-body
- Open Access
- 21 October 2025
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 11 (S1) , 1-15
Abstracts from the Sixth Bioelectronic Medicine Summit: Neurotechnologies for Individuals and Communities
- 21 October 2025
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 11 (S1) , 1-15
Open AccessAbstracts from the Sixth Bioelectronic Medicine Summit: Neurotechnologies for Individuals and Communities
- Open Access
- 13 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Control of spatiotemporal activation of organ-specific fibers in the swine vagus nerve by intermittent interferential current stimulation
Vagus nerve stimulation (VNS) is emerging as potential treatment for several chronic diseases. However, limited control of fiber activation, e.g., to promote desired effects over side effects, restricts clinical translation. Towards that goal, we describe a VNS method consisting of intermittent, interferential sinusoidal current stimulation (i2CS) through multi-contact epineural cuffs. In experiments in anesthetized swine, i2CS elicits nerve potentials and organ responses, from lungs and laryngeal muscles, that are distinct from equivalent non-interferential sinusoidal stimulation. Resection and micro-CT imaging of a previously stimulated nerve, to resolve anatomical trajectories of nerve fascicles, demonstrate that i2CS responses are explained by activation of organ-specific fascicles rather than the entire nerve. Physiological responses in swine and activity of single fibers in anatomically realistic, physiologically validated biophysical vagus nerve models indicate that i2CS reduces fiber activation at the interference focus. Experimental and modeling results demonstrate that current steering and beat and repetition frequencies predictably shape the spatiotemporal pattern of fiber activation, allowing tunable and precise control of nerve and organ responses. When compared to equivalent sinusoidal stimulation in the same animals, i2CS produces reduced levels of a side-effect by larger laryngeal fibers, while attaining similar levels of a desired effect by smaller bronchopulmonary fibers.
- 13 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessControl of spatiotemporal activation of organ-specific fibers in the swine vagus nerve by intermittent interferential current stimulation
Vagus nerve stimulation (VNS) is emerging as potential treatment for several chronic diseases. However, limited control of fiber activation, e.g., to promote desired effects over side effects, restricts clinical translation. Towards that goal, we describe a VNS method consisting of intermittent, interferential sinusoidal current stimulation (i2CS) through multi-contact epineural cuffs. In experiments in anesthetized swine, i2CS elicits nerve potentials and organ responses, from lungs and laryngeal muscles, that are distinct from equivalent non-interferential sinusoidal stimulation. Resection and micro-CT imaging of a previously stimulated nerve, to resolve anatomical trajectories of nerve fascicles, demonstrate that i2CS responses are explained by activation of organ-specific fascicles rather than the entire nerve. Physiological responses in swine and activity of single fibers in anatomically realistic, physiologically validated biophysical vagus nerve models indicate that i2CS reduces fiber activation at the interference focus. Experimental and modeling results demonstrate that current steering and beat and repetition frequencies predictably shape the spatiotemporal pattern of fiber activation, allowing tunable and precise control of nerve and organ responses. When compared to equivalent sinusoidal stimulation in the same animals, i2CS produces reduced levels of a side-effect by larger laryngeal fibers, while attaining similar levels of a desired effect by smaller bronchopulmonary fibers.
- Open Access
Control of spatiotemporal activation of organ-specific fibers in the vagus nerve by intermittent interferential current stimulation
Vagus nerve stimulation (VNS) is emerging as potential treatment for several chronic diseases, however, limited control of fiber activation to promote desired effects over side effects restricts clinical translation. Here we describe a new VNS method that relies on intermittent, interferential sinusoidal current stimulation (i 2 CS) through implanted, multi-contact epineural cuffs. In swine, i 2 CS elicits specific nerve potentials and end organ responses, distinct from equivalent non-interferential sinusoidal stimulation. Comparing experimental results with anatomical trajectories of nerve fascicles from end organs to the stimulation electrode indicates that i 2 CS activates organ-specific fascicles rather than the entire nerve. Experimental results and anatomically realistic, physiologically validated biophysical models of the vagus nerve demonstrate that i 2 CS reduces fiber activation at the focus of interference. Current steering and repetition frequency determine spatiotemporal pattern of vagal fiber activation, allowing tunable and precise control of neural and organ responses. In experiments in a cohort of anesthetized swine, i 2 CS has improved selectivity for a desired effect, mediated by smaller bronchopulmonary fibers, over a side effect, mediated by larger laryngeal fibers, compared to non-interferential sinusoidal or square pulse VNS.
Open AccessControl of spatiotemporal activation of organ-specific fibers in the vagus nerve by intermittent interferential current stimulation
Vagus nerve stimulation (VNS) is emerging as potential treatment for several chronic diseases, however, limited control of fiber activation to promote desired effects over side effects restricts clinical translation. Here we describe a new VNS method that relies on intermittent, interferential sinusoidal current stimulation (i 2 CS) through implanted, multi-contact epineural cuffs. In swine, i 2 CS elicits specific nerve potentials and end organ responses, distinct from equivalent non-interferential sinusoidal stimulation. Comparing experimental results with anatomical trajectories of nerve fascicles from end organs to the stimulation electrode indicates that i 2 CS activates organ-specific fascicles rather than the entire nerve. Experimental results and anatomically realistic, physiologically validated biophysical models of the vagus nerve demonstrate that i 2 CS reduces fiber activation at the focus of interference. Current steering and repetition frequency determine spatiotemporal pattern of vagal fiber activation, allowing tunable and precise control of neural and organ responses. In experiments in a cohort of anesthetized swine, i 2 CS has improved selectivity for a desired effect, mediated by smaller bronchopulmonary fibers, over a side effect, mediated by larger laryngeal fibers, compared to non-interferential sinusoidal or square pulse VNS.
- Open Access
- 16 October 2024
- Published by Springer Nature in Research Square
Control of spatiotemporal activation of organ-specific fibers in the vagus nerve by intermittent interferential current stimulation
Vagus nerve stimulation (VNS) is emerging as potential treatment for several chronic diseases, however, limited control of fiber activation to promote desired effects over side effects restricts clinical translation. Here we describe a new VNS method that relies on intermittent, interferential sinusoidal current stimulation (i2CS) through implanted, multi-contact epineural cuffs. In swine, i2CS elicits specific nerve potentials and end organ responses, distinct from equivalent non-interferential sinusoidal stimulation. Comparing experimental results with anatomical trajectories of nerve fascicles from end organs to the stimulation electrode indicates that i2CS activates organ-specific fascicles rather than the entire nerve. Experimental results and anatomically realistic, physiologically validated biophysical models of the vagus nerve demonstrate that i2CS reduces fiber activation at the focus of interference. Current steering and repetition frequency determine spatiotemporal pattern of vagal fiber activation, allowing tunable and precise control of neural and organ responses. In experiments in a cohort of anesthetized swine, i2CS has improved selectivity for a desired effect, mediated by smaller bronchopulmonary fibers, over a side effect, mediated by larger laryngeal fibers, compared to non-interferential sinusoidal or square pulse VNS.
- 16 October 2024
- Published by Springer Nature in Research Square
Open AccessControl of spatiotemporal activation of organ-specific fibers in the vagus nerve by intermittent interferential current stimulation
Vagus nerve stimulation (VNS) is emerging as potential treatment for several chronic diseases, however, limited control of fiber activation to promote desired effects over side effects restricts clinical translation. Here we describe a new VNS method that relies on intermittent, interferential sinusoidal current stimulation (i2CS) through implanted, multi-contact epineural cuffs. In swine, i2CS elicits specific nerve potentials and end organ responses, distinct from equivalent non-interferential sinusoidal stimulation. Comparing experimental results with anatomical trajectories of nerve fascicles from end organs to the stimulation electrode indicates that i2CS activates organ-specific fascicles rather than the entire nerve. Experimental results and anatomically realistic, physiologically validated biophysical models of the vagus nerve demonstrate that i2CS reduces fiber activation at the focus of interference. Current steering and repetition frequency determine spatiotemporal pattern of vagal fiber activation, allowing tunable and precise control of neural and organ responses. In experiments in a cohort of anesthetized swine, i2CS has improved selectivity for a desired effect, mediated by smaller bronchopulmonary fibers, over a side effect, mediated by larger laryngeal fibers, compared to non-interferential sinusoidal or square pulse VNS.
- 3 January 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (9) , 1278-1279
A randomized, double‐blind, sham‐controlled, clinical trial of auricular vagus nerve stimulation for the treatment of active rheumatoid arthritis: comment on the article by Baker et al
- 3 January 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (9) , 1278-1279
A randomized, double‐blind, sham‐controlled, clinical trial of auricular vagus nerve stimulation for the treatment of active rheumatoid arthritis: comment on the article by Baker et al
- Open Access
- 17 October 2023
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 20 (1) , 1-15
Voltammetry in the spleen assesses real-time immunomodulatory norepinephrine release elicited by autonomic neurostimulation
The noradrenergic innervation of the spleen is implicated in the autonomic control of inflammation and has been the target of neurostimulation therapies for inflammatory diseases. However, there is no real-time marker of its successful activation, which hinders the development of anti-inflammatory neurostimulation therapies and mechanistic studies in anti-inflammatory neural circuits. In mice, we performed fast-scan cyclic voltammetry (FSCV) in the spleen during intravenous injections of norepinephrine (NE), and during stimulation of the vagus, splanchnic, or splenic nerves. We defined the stimulus-elicited charge generated at the oxidation potential for NE (~ 0.88 V) as the “NE voltammetry signal” and quantified the dependence of the signal on NE dose and intensity of neurostimulation. We correlated the NE voltammetry signal with the anti-inflammatory effect of splenic nerve stimulation (SpNS) in a model of lipopolysaccharide- (LPS) induced endotoxemia, quantified as suppression of TNF release. The NE voltammetry signal is proportional to the estimated peak NE blood concentration, with 0.1 μg/mL detection threshold. In response to SpNS, the signal increases within seconds, returns to baseline minutes later, and is blocked by interventions that deplete NE or inhibit NE release. The signal is elicited by efferent, but not afferent, electrical or optogenetic vagus nerve stimulation, and by splanchnic nerve stimulation. The magnitude of the signal during SpNS is inversely correlated with subsequent TNF suppression in endotoxemia and explains 40% of the variance in TNF measurements. FSCV in the spleen provides a marker for real-time monitoring of anti-inflammatory activation of the splenic innervation during autonomic stimulation.
- 17 October 2023
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 20 (1) , 1-15
Open AccessVoltammetry in the spleen assesses real-time immunomodulatory norepinephrine release elicited by autonomic neurostimulation
The noradrenergic innervation of the spleen is implicated in the autonomic control of inflammation and has been the target of neurostimulation therapies for inflammatory diseases. However, there is no real-time marker of its successful activation, which hinders the development of anti-inflammatory neurostimulation therapies and mechanistic studies in anti-inflammatory neural circuits. In mice, we performed fast-scan cyclic voltammetry (FSCV) in the spleen during intravenous injections of norepinephrine (NE), and during stimulation of the vagus, splanchnic, or splenic nerves. We defined the stimulus-elicited charge generated at the oxidation potential for NE (~ 0.88 V) as the “NE voltammetry signal” and quantified the dependence of the signal on NE dose and intensity of neurostimulation. We correlated the NE voltammetry signal with the anti-inflammatory effect of splenic nerve stimulation (SpNS) in a model of lipopolysaccharide- (LPS) induced endotoxemia, quantified as suppression of TNF release. The NE voltammetry signal is proportional to the estimated peak NE blood concentration, with 0.1 μg/mL detection threshold. In response to SpNS, the signal increases within seconds, returns to baseline minutes later, and is blocked by interventions that deplete NE or inhibit NE release. The signal is elicited by efferent, but not afferent, electrical or optogenetic vagus nerve stimulation, and by splanchnic nerve stimulation. The magnitude of the signal during SpNS is inversely correlated with subsequent TNF suppression in endotoxemia and explains 40% of the variance in TNF measurements. FSCV in the spleen provides a marker for real-time monitoring of anti-inflammatory activation of the splenic innervation during autonomic stimulation.
- Open Access
- 5 October 2023
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 9 (1) , 1-9
The Fifth Bioelectronic Medicine Summit: today’s tools, tomorrow’s therapies
The emerging field of bioelectronic medicine (BEM) is poised to make a significant impact on the treatment of several neurological and inflammatory disorders. With several BEM therapies being recently approved for clinical use and others in late-phase clinical trials, the 2022 BEM summit was a timely scientific meeting convening a wide range of experts to discuss the latest developments in the field. The BEM Summit was held over two days in New York with more than thirty-five invited speakers and panelists comprised of researchers and experts from both academia and industry. The goal of the meeting was to bring international leaders together to discuss advances and cultivate collaborations in this emerging field that incorporates aspects of neuroscience, physiology, molecular medicine, engineering, and technology. This Meeting Report recaps the latest findings discussed at the Meeting and summarizes the main developments in this rapidly advancing interdisciplinary field. Our hope is that this Meeting Report will encourage researchers from academia and industry to push the field forward and generate new multidisciplinary collaborations that will form the basis of new discoveries that we can discuss at the next BEM Summit.
- 5 October 2023
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 9 (1) , 1-9
Open AccessThe Fifth Bioelectronic Medicine Summit: today’s tools, tomorrow’s therapies
The emerging field of bioelectronic medicine (BEM) is poised to make a significant impact on the treatment of several neurological and inflammatory disorders. With several BEM therapies being recently approved for clinical use and others in late-phase clinical trials, the 2022 BEM summit was a timely scientific meeting convening a wide range of experts to discuss the latest developments in the field. The BEM Summit was held over two days in New York with more than thirty-five invited speakers and panelists comprised of researchers and experts from both academia and industry. The goal of the meeting was to bring international leaders together to discuss advances and cultivate collaborations in this emerging field that incorporates aspects of neuroscience, physiology, molecular medicine, engineering, and technology. This Meeting Report recaps the latest findings discussed at the Meeting and summarizes the main developments in this rapidly advancing interdisciplinary field. Our hope is that this Meeting Report will encourage researchers from academia and industry to push the field forward and generate new multidisciplinary collaborations that will form the basis of new discoveries that we can discuss at the next BEM Summit.
- Open Access
- 5 October 2022
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 8 (1) , 1-13
High-frequency electrical stimulation attenuates neuronal release of inflammatory mediators and ameliorates neuropathic pain
Background: Neuroinflammation is an important driver of acute and chronic pain states. Therefore, targeting molecular mediators of neuroinflammation may present an opportunity for developing novel pain therapies. In preclinical models of neuroinflammatory pain, calcitonin gene-related peptide (CGRP), substance P and high mobility group box 1 protein (HMGB1) are molecules synthesized and released by sensory neurons which activate inflammation and pain. High-frequency electrical nerve stimulation (HFES) has achieved clinical success as an analgesic modality, but the underlying mechanism is unknown. Here, we reasoned that HFES inhibits neuroinflammatory mediator release by sensory neurons to reduce pain. Methods: Utilizing in vitro and in vivo assays, we assessed the modulating effects of HFES on neuroinflammatory mediator release by activated sensory neurons. Dorsal root ganglia (DRG) neurons harvested from wildtype or transgenic mice expressing channelrhodopsin-2 (ChR2) were cultured on micro-electrode arrays, and effect of HFES on optogenetic- or capsaicin-induced neuroinflammatory mediator release was determined. Additionally, the effects of HFES on local neuroinflammatory mediator release and hyperalgesia was assessed in vivo using optogenetic paw stimulation and the neuropathic pain model of chronic constriction injury (CCI) of the sciatic nerve. Results: Light- or capsaicin-evoked neuroinflammatory mediator release from cultured transgenic DRG sensory neurons was significantly reduced by concurrent HFES (10 kHz). In agreement with these findings, elevated levels of neuroinflammatory mediators were detected in the affected paw following optogenetic stimulation or CCI and were significantly attenuated using HFES (20.6 kHz for 10 min) delivered once daily for 3 days. Conclusion: These studies reveal a previously unidentified mechanism for the pain-modulating effect of HFES in the setting of acute and chronic nerve injury. The results support the mechanistic insight that HFES may reset sensory neurons into a less pro-inflammatory state via inhibiting the release of neuroinflammatory mediators resulting in reduced inflammation and pain.
- 5 October 2022
- Published by Springer Nature in Bioelectronic Medicine
- Vol. 8 (1) , 1-13
Open AccessHigh-frequency electrical stimulation attenuates neuronal release of inflammatory mediators and ameliorates neuropathic pain
Background: Neuroinflammation is an important driver of acute and chronic pain states. Therefore, targeting molecular mediators of neuroinflammation may present an opportunity for developing novel pain therapies. In preclinical models of neuroinflammatory pain, calcitonin gene-related peptide (CGRP), substance P and high mobility group box 1 protein (HMGB1) are molecules synthesized and released by sensory neurons which activate inflammation and pain. High-frequency electrical nerve stimulation (HFES) has achieved clinical success as an analgesic modality, but the underlying mechanism is unknown. Here, we reasoned that HFES inhibits neuroinflammatory mediator release by sensory neurons to reduce pain. Methods: Utilizing in vitro and in vivo assays, we assessed the modulating effects of HFES on neuroinflammatory mediator release by activated sensory neurons. Dorsal root ganglia (DRG) neurons harvested from wildtype or transgenic mice expressing channelrhodopsin-2 (ChR2) were cultured on micro-electrode arrays, and effect of HFES on optogenetic- or capsaicin-induced neuroinflammatory mediator release was determined. Additionally, the effects of HFES on local neuroinflammatory mediator release and hyperalgesia was assessed in vivo using optogenetic paw stimulation and the neuropathic pain model of chronic constriction injury (CCI) of the sciatic nerve. Results: Light- or capsaicin-evoked neuroinflammatory mediator release from cultured transgenic DRG sensory neurons was significantly reduced by concurrent HFES (10 kHz). In agreement with these findings, elevated levels of neuroinflammatory mediators were detected in the affected paw following optogenetic stimulation or CCI and were significantly attenuated using HFES (20.6 kHz for 10 min) delivered once daily for 3 days. Conclusion: These studies reveal a previously unidentified mechanism for the pain-modulating effect of HFES in the setting of acute and chronic nerve injury. The results support the mechanistic insight that HFES may reset sensory neurons into a less pro-inflammatory state via inhibiting the release of neuroinflammatory mediators resulting in reduced inflammation and pain.